Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 2
2004 3
2005 4
2006 5
2007 2
2008 3
2009 7
2010 8
2011 5
2012 9
2013 10
2014 8
2015 19
2016 18
2017 20
2018 30
2019 20
2020 28
2021 23
2022 25
2023 36
2024 38
2025 31
2026 20

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

328 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studies.
Veenstra CR, Ngai LL, Gradowska P, Versluis J, Reuvekamp T, Kelder A, Scholten W, Snel S, Tettero JM, Bachas C, Breems DA, Fischer T, Gjertsen BT, Griskevicius L, Juliusson G, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Alhan C, Westers TM, de Leeuw DC, Löwenberg B, Ossenkoppele GJ, Cloos J, van de Loosdrecht AA. Veenstra CR, et al. Among authors: pabst t. Hemasphere. 2026 May 21;10(5):e70379. doi: 10.1002/hem3.70379. eCollection 2026 May. Hemasphere. 2026. PMID: 42256549 Free PMC article.
Chimeric antigen receptor T-cell therapy is equally effective and safe in older (≥70) and younger patients with multiple myeloma: a multicenter retrospective analysis.
Berning P, Maulhardt M, Boyadzhiev H, Albici AM, Janjetovic S, Ossami Saidy A, Schultze-Florey C, Call S, Stölzel F, Brioli A, Daskalakis M, Knust J, Hasenkamp J, Wurm-Kuczera R, Pohlmann A, Stelljes M, Khandanpour C, Bacher U, Boquoi A, Heidel FH, Reinhardt HC, Wulf G, Schub N, von Tresckow B, Lenz G, Pabst T, Shumilov E. Berning P, et al. Among authors: pabst t. Blood Cancer J. 2026 Jun 2;16(1):88. doi: 10.1038/s41408-026-01531-w. Blood Cancer J. 2026. PMID: 42230557 Free PMC article. No abstract available.
Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.
Wollnitza S, Ventura D, Teichert M, Freisleben F, Boyadzhiev H, Seifert R, Amon M, Barbato F, Scholz JK, Beck M, Kerkhoff A, Behringer A, Backhaus P, Pohlmann A, Schindler P, Roll W, Müller F, Novak U, Pabst T, Schäfers M, von Tresckow B, Shumilov E, Lenz G. Wollnitza S, et al. Among authors: pabst t. Eur J Nucl Med Mol Imaging. 2026 Jun 1. doi: 10.1007/s00259-026-07958-4. Online ahead of print. Eur J Nucl Med Mol Imaging. 2026. PMID: 42223630
Temporal trends and prognostic factors in critically ill adult patients with acute leukemia: an individual participant data meta-analysis.
Chean D, Dupont T, Nates JL, Manjappachar NK, Medic M, Aygencel G, Orvain C, Kouatchet A, Sheshadri A, Haque TK, Russell L, Pabst T, Turkoglu M, Ostermann M, Soares M, Cetintepe T, Buckstein R, Issa N, Mokart D, Caruso P, Cornejo-Juarez P, Schnell D, Lahmer T, Fodil S, Lengliné E, Luque-Paz D, Lemiale V, Poole D, Darmon M, Azoulay E. Chean D, et al. Among authors: pabst t. Intensive Care Med. 2026 May 4. doi: 10.1007/s00134-026-08449-8. Online ahead of print. Intensive Care Med. 2026. PMID: 42081104
Contrast-enhanced CT for attenuation correction in ultra-high sensitivity long-axial field-of-view lymphoma PET: amplified quantification problems?
Penner JL, Blomgren A, Weissensee A, Amon M, Acikgöz S, Mingels C, Ferdinandus J, Aghapour Zangeneh F, Novak U, Pabst T, Rominger A, Shi K, Sari H, Seifert R. Penner JL, et al. Among authors: pabst t. EJNMMI Phys. 2026 Apr 13;13(1):50. doi: 10.1186/s40658-026-00866-4. EJNMMI Phys. 2026. PMID: 41973274 Free PMC article.
Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.
Shumilov E, Wurm-Kuczera R, Kauer J, Wang M, Mazzeo P, Boyadzhiev H, Gebauer N, Holtick U, Hölscher A, Teichert M, Nierychlewska PM, Kimmich C, Berning P, Melchardt T, Zeremski V, Wirths C, Nakov P, Schultze-Florey C, Velazquez GF, Lesan V, Krämer I, Kaiser F, Vehling-Kaiser U, Ossami-Saidy A, Huber H, Behringer A, Bentz M, Scholz JK, Gödel P, Schnetzke U, Vucinic V, Shorb E, Ghandili S, Kerkhoff A, Scheich S, Aydin S, Mayer K, Bacher U, Wille K, Glass B, Oellerich T, Ayuk F, Heidel F, Thurner L, Lutz M, Hänel M, Scholz CW, Tometten M, Pott C, Dreger P, Mougiakakos D, Dietrich S, Derenzini E, Chapuy B, Tresckow BV, Pabst T, Müller F, Lenz G. Shumilov E, et al. Among authors: pabst t. Haematologica. 2026 Apr 2. doi: 10.3324/haematol.2025.300063. Online ahead of print. Haematologica. 2026. PMID: 41924925 Free article.
328 results